scholarly journals KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients

2014 ◽  
Vol 15 (7) ◽  
pp. 495-499 ◽  
Author(s):  
A Gonzalez ◽  
◽  
K Schmitter ◽  
H H Hirsch ◽  
C Garzoni ◽  
...  
Keyword(s):  
Prospective Study ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients ◽  
A Prospective Study

scholarly journals Electronic Estimations of Renal Function Are Inaccurate in Solid-Organ Transplant Recipients and Can Result in Significant Underdosing of Prophylactic Valganciclovir

2013 ◽  
Vol 57 (8) ◽  
pp. 4058-4060 ◽  
Author(s):  
J. Trevillyan ◽  
P. Angus ◽  
E. Shelton ◽  
J. Whitlam ◽  
F. Ierino ◽  
...  
Keyword(s):  
Filtration Rate ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Urine Creatinine ◽  
Solid Organ Transplant Recipients ◽  
A Prospective Study ◽  
Cmv Prophylaxis

ABSTRACTIn a prospective study of solid-organ transplant recipients (n= 22; 15 hepatic and 7 renal) receiving valganciclovir for cytomegalovirus (CMV) prophylaxis, electronic estimation of glomerular filtration rate (eGFR) underestimated the true GFR (24-h urine creatinine clearance) by >20% in 14/22 (63.6%). Its use was associated with inappropriate underdosing of valganciclovir, while the Cockroft-Gault equation was accurate in 21/22 patients (95.4%). Subtherapeutic ganciclovir levels (≤0.6 mg/liter) were common, occurring in 10/22 patients (45.4%); 7 had severely deficient levels (<0.3 mg/liter).

Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients

Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Efrat Solomon-Cohen ◽  
Shiran Reiss-Huss ◽  
Emmilia Hodak ◽  
Batya Davidovici
Keyword(s):  
Secondary Prevention ◽  
Cell Carcinoma ◽  
Low Dose ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Pretreatment Period ◽  
Solid Organ Transplant Recipients

<b><i>Background:</i></b> Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation. <b><i>Objective:</i></b> Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs. <b><i>Methods:</i></b> This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010–2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period. <b><i>Results:</i></b> The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, –53% <i>p</i> = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma. <b><i>Conclusion:</i></b> This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.

Sign in / Sign up

Export Citation Format

Share Document